CURE EB (FORMERLY KNOWN AS SOHANA RESEARCH FUND) — grant history
Latest income
£3.5m
Grants listed (FY2025)
26
Listed grants total
£3.4m
Accounts grants total
£1.2m
listed grants do not fully reconcile with the accounts total — list may be partialextracted from its FY2025 accounts
Application guidance — from the funder’s own website
- What they don’t fund: We do not generally fund basic laboratory research, including animal studies. Animal studies may be funded as part of later stage research prior to embarking on a proof of concept clinical trial.
What changed: FY2024 → FY2025
| Change | Grantee | FY2024 | FY2025 |
|---|---|---|---|
| new | Nanocure | — | £639k |
| new | Bespoke Therapy | — | £359k |
| new | Decorin | — | £359k |
| new | EB Graft | — | £326k |
| new | Therapy for RDEBsec | — | £215k |
| new | Spray on Skin | — | £215k |
| new | EB Cancer Therapy | — | £100k |
| new | Base & prime editing strategies for RDEB | — | £80k |
| up | UC3 Madrid | £39k | £351k |
| down | University of Colorado | £639k | £267k |
| down | Inserm | £703k | £147k |
| up | University of Minnesota | £200 | £39k |
| not listed | Kings College London | £559k | — |
Grants made, per its accounts filings
| Recipient | Year | Amount | Purpose |
|---|---|---|---|
| Nanocure | FY2025 | £639k | Nanocure |
| Bespoke Therapy | FY2025 | £359k | Bespoke Therapy |
| Decorin | FY2025 | £359k | Decorin |
| UC3 Madrid | FY2025 | £351k | Gene Editing Trial |
| EB Graft | FY2025 | £326k | EB Graft |
| University of Colorado | FY2025 | £267k | Spray on Skin |
| Therapy for RDEBsec | FY2025 | £215k | Therapy for RDEBsec |
| Spray on Skin | FY2025 | £215k | Spray on Skin |
| Inserm | FY2025 | £147k | SIRNA |
| EB Cancer Therapy | FY2025 | £100k | EB Cancer Therapy |
| Bespoke Therapy | FY2025 | £80k | Bespoke Therapy |
| Base & prime editing strategies for RDEB | FY2025 | £80k | Base & prime editing strategies for RDEB |
| EB Graft | FY2025 | £67k | EB Graft |
| Oligo | FY2025 | £45k | Oligo |
| University of Minnesota | FY2025 | £39k | Nanocol |
| Gene Editing Trial - UC3 Madrid | FY2025 | £38k | Gene Editing Trial |
| EB Cancer Therapy | FY2025 | £17k | EB Cancer Therapy |
| Chemoprevention | FY2025 | £13k | Chemoprevention |
| EBCancer Therapy | FY2025 | £13k | EBCancer Therapy |
| SIRNA | FY2025 | £10k | SIRNA |
| James Lind Alliance | FY2025 | £10k | James Lind Alliance |
| JEBAirway Disease | FY2025 | £10k | JEBAirway Disease |
| Decorin | FY2025 | £1k | Decorin |
| JEBAirway Disease | FY2025 | £387 | JEBAirway Disease |
| mRNA-based base editing | FY2025 | £272 | mRNA-based base editing |
| Base & Prime Editing strategies for RDEB | FY2025 | £235 | Base & Prime Editing strategies for RDEB |
| Inserm | FY2024 | £703k | SIRNA |
| University of Colorado | FY2024 | £639k | PASTE- Superexon Replacement |
| Kings College London | FY2024 | £559k | Nanocol |
| Kings College London | FY2024 | £351k | Base & Prime Editing strategies for RDEB |
| Unknown | FY2024 | Unverified read£267k | Other costs |
| Unknown | FY2024 | Unverified read£155k | Decorin |
| Kings College London | FY2024 | £147k | Base Editing of RDEB fibroblasts |
| Unknown | FY2024 | Unverified read£95k | EBGraft |
| Unknown | FY2024 | Unverified read£80k | Bespoke Therapy |
| University of Colorado | FY2024 | £67k | Spray on Skin |
| Unknown | FY2024 | Unverified read£50k | JEBAirway Disease |
| Unknown | FY2024 | Unverified read£49k | Oligo |
| UC3 Madrid | FY2024 | £39k | Gene Editing Trial |
| Unknown | FY2024 | Unverified read£17k | Other costs |
| Unknown | FY2024 | Unverified read£14k | EBCancer Therapy |
| University of Minnesota | FY2024 | £200 | Nanocol |
| Kings College London - Base Editing of RDEB fibroblasts | FY2023 | £703k | Research projects |
| University of Colorado – Spray on Skin | FY2023 | £155k | Research projects |
| Kings College London - Nanocol | FY2023 | £95k | Research projects |
| PASTE – Superexon Replacement | FY2023 | £50k | Research projects |
| UCL Gene Editing | FY2023 | £49k | Research projects |
| Universidad Carlos III de Madrid - Gene Editing Trial | FY2023 | £14k | Research projects |
| University of Minnesota - Nanocol | FY2023 | £200 | Research projects |
| Inserm - SIRNA | FY2023 | amount not stated | Research projects |
| Inserm - Oligo | FY2023 | amount not stated | Research projects |
| Inserm - EB Graft | FY2023 | amount not stated | Research projects |
| St Thomas’ Hospital, London - Rigosertib | FY2023 | amount not stated | Research projects |
| Thomas Jefferson - Rigosertib | FY2023 | amount not stated | Research projects |
| Great Ormond Street - Gene Therapy | FY2023 | amount not stated | Research projects |
| Kings College London | FY2022 | £208k | Base Editing of RDEB fibroblasts |
| EB Graft | FY2022 | £151k | |
| Great Ormond Street | FY2022 | £140k | Mission EB |
| Debra UK | FY2022 | £127k | Gene therapy |
| St Thomas' Hospital, London | FY2022 | £127k | Rigosertib |
| Thomas Jefferson | FY2022 | £127k | Rigosertib |
| University of Minnesota | FY2022 | £83k | Nanocol |
| Kings College London | FY2022 | £82k | Nanocol |
| Stanford University | FY2022 | £77k | EB IPS Cell Consortium |
| Oligo | FY2022 | £32k | |
| Universidad Carlos III de Madrid | FY2022 | £27k | Gene Editing Trial |
| UCL | FY2022 | £18k | Gene Editing |
| Kings College London - Nanocol | FY2021 | £195k | |
| UCL Gene Editing | FY2021 | £150k | |
| University of Minnesota - Next Gene Genome Sequencing/Nanocol | FY2021 | £113k | |
| Universidad Carlos III de Madrid - Gene Editing Trial | FY2021 | £106k | |
| Great Ormond Street - Mission EB | FY2021 | £100k | |
| EB Therapeutics | FY2021 | £92k | |
| Stanford University - EB IPS Cell Consortium | FY2021 | £65k | |
| EB Graft | FY2021 | £37k | |
| Colorado Gates | FY2021 | £36k | |
| University of Minnesota | FY2020 | £248k | Next Gene Genome Sequencing |
| Gene Editing Trial - Madrid | FY2020 | £136k | Gene Editing Trial |
| Colorado Gates | FY2020 | £107k | Colorado Gates |
| UCL Gene Editing | FY2020 | £60k | UCL Gene Editing |
| Kings College London - Nanocol | FY2020 | £41k | Kings College London - Nanocol |
| DEBRA - Lenticol F clinical trial | FY2020 | amount not stated | DEBRA - Lenticol F clinical trial |